Abstract
Background: Despite the usefulness of CA 19-9 in the diagnosis and prognosis of pancreatic cancer, cholestasis can falsely elevate CA 19-9 levels, which contributes to limited clinical utility in patients with biliary obstruction. This study was designed to evaluate the usefulness of adjusted preoperative CA 19-9 levels in predicting a prognosis of pancreatic cancer. Methods: The available medical records of patients with resected pancreatic cancer from January 1990 to June 2005 were retrospectively viewed at Yonsei Medical Center, Seoul, Korea. The adjusted CA 19-9 value was obtained by dividing the serum CA 19-9 level by the values of serum bilirubin in case of bilirubin ≳2 mg/dL. Disease-free survival was evaluated according to the adjusted preoperative CA 19-9 value. Results: Sixty-one patients were investigated. Their adjusted preoperative CA 19-9 values were significantly different from the actual baseline CA 19-9 value (129.4 ± 225.2 U/mL, versus 442.1 ± 645.5 U/mL, P < 0.0001). On univariate analysis, peripancreatic microscopic invasion (P = 0.0142), lymphovascular invasion (P = 0.0038), and adjusted preoperative CA 19-9 ≥ 50 U/mL (P = 0.0049) were predictive factors for cancer recurrence after curative resection. Adjusted preoperative CA 19-9 ≥ 50 U/mL (Exp (B) = 2.097, P = 0.027) was an independent predictive factor in multivariate analysis. Conclusions: The adjusted preoperative CA 19-9 value can predict the risk of recurrence after curative resection of pancreatic cancer. Interpreting the preoperative CA 19-9 value adjusted to the serum bilirubin values seems to be more reasonable in evaluating prognosis of pancreatic cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 31-35 |
| Number of pages | 5 |
| Journal | Journal of Surgical Research |
| Volume | 140 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2007 Jun 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Surgery
Cite this
}
The Use of Adjusted Preoperative CA 19-9 to Predict the Recurrence of Resectable Pancreatic Cancer. / Kang, Chang Moo; Kim, Jun Young; Choi, Gi Hong; Kim, Kyung Sik; Choi, Jin Sub; Lee, Woo Jung; Kim, Byong Ro.
In: Journal of Surgical Research, Vol. 140, No. 1, 01.06.2007, p. 31-35.Research output: Contribution to journal › Article
TY - JOUR
T1 - The Use of Adjusted Preoperative CA 19-9 to Predict the Recurrence of Resectable Pancreatic Cancer
AU - Kang, Chang Moo
AU - Kim, Jun Young
AU - Choi, Gi Hong
AU - Kim, Kyung Sik
AU - Choi, Jin Sub
AU - Lee, Woo Jung
AU - Kim, Byong Ro
PY - 2007/6/1
Y1 - 2007/6/1
N2 - Background: Despite the usefulness of CA 19-9 in the diagnosis and prognosis of pancreatic cancer, cholestasis can falsely elevate CA 19-9 levels, which contributes to limited clinical utility in patients with biliary obstruction. This study was designed to evaluate the usefulness of adjusted preoperative CA 19-9 levels in predicting a prognosis of pancreatic cancer. Methods: The available medical records of patients with resected pancreatic cancer from January 1990 to June 2005 were retrospectively viewed at Yonsei Medical Center, Seoul, Korea. The adjusted CA 19-9 value was obtained by dividing the serum CA 19-9 level by the values of serum bilirubin in case of bilirubin ≳2 mg/dL. Disease-free survival was evaluated according to the adjusted preoperative CA 19-9 value. Results: Sixty-one patients were investigated. Their adjusted preoperative CA 19-9 values were significantly different from the actual baseline CA 19-9 value (129.4 ± 225.2 U/mL, versus 442.1 ± 645.5 U/mL, P < 0.0001). On univariate analysis, peripancreatic microscopic invasion (P = 0.0142), lymphovascular invasion (P = 0.0038), and adjusted preoperative CA 19-9 ≥ 50 U/mL (P = 0.0049) were predictive factors for cancer recurrence after curative resection. Adjusted preoperative CA 19-9 ≥ 50 U/mL (Exp (B) = 2.097, P = 0.027) was an independent predictive factor in multivariate analysis. Conclusions: The adjusted preoperative CA 19-9 value can predict the risk of recurrence after curative resection of pancreatic cancer. Interpreting the preoperative CA 19-9 value adjusted to the serum bilirubin values seems to be more reasonable in evaluating prognosis of pancreatic cancer.
AB - Background: Despite the usefulness of CA 19-9 in the diagnosis and prognosis of pancreatic cancer, cholestasis can falsely elevate CA 19-9 levels, which contributes to limited clinical utility in patients with biliary obstruction. This study was designed to evaluate the usefulness of adjusted preoperative CA 19-9 levels in predicting a prognosis of pancreatic cancer. Methods: The available medical records of patients with resected pancreatic cancer from January 1990 to June 2005 were retrospectively viewed at Yonsei Medical Center, Seoul, Korea. The adjusted CA 19-9 value was obtained by dividing the serum CA 19-9 level by the values of serum bilirubin in case of bilirubin ≳2 mg/dL. Disease-free survival was evaluated according to the adjusted preoperative CA 19-9 value. Results: Sixty-one patients were investigated. Their adjusted preoperative CA 19-9 values were significantly different from the actual baseline CA 19-9 value (129.4 ± 225.2 U/mL, versus 442.1 ± 645.5 U/mL, P < 0.0001). On univariate analysis, peripancreatic microscopic invasion (P = 0.0142), lymphovascular invasion (P = 0.0038), and adjusted preoperative CA 19-9 ≥ 50 U/mL (P = 0.0049) were predictive factors for cancer recurrence after curative resection. Adjusted preoperative CA 19-9 ≥ 50 U/mL (Exp (B) = 2.097, P = 0.027) was an independent predictive factor in multivariate analysis. Conclusions: The adjusted preoperative CA 19-9 value can predict the risk of recurrence after curative resection of pancreatic cancer. Interpreting the preoperative CA 19-9 value adjusted to the serum bilirubin values seems to be more reasonable in evaluating prognosis of pancreatic cancer.
UR - http://www.scopus.com/inward/record.url?scp=34247620806&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34247620806&partnerID=8YFLogxK
U2 - 10.1016/j.jss.2006.10.007
DO - 10.1016/j.jss.2006.10.007
M3 - Article
C2 - 17418869
AN - SCOPUS:34247620806
VL - 140
SP - 31
EP - 35
JO - Journal of Surgical Research
JF - Journal of Surgical Research
SN - 0022-4804
IS - 1
ER -